Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Dose Study of HS-20004 in Healthy Chinese Subjects
NCT02746315Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2014
- Primary completion
- Feb 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of noiiglutide in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Number of treatment emergent adverse events. Started Oct 2014; status: completed.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02746315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746315.